Skip to content

Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion

Medical Abortion

National multi-center non interventional study aiming at investigating the effectiveness and safety of the combination mifepristone-misoprostol prescribed in Canada to women for medical termination of pregnancy at or before 63 days gestational age through a multi-center prospective non interventional study design.

null

Participation Requirements

  • Sex:

    FEMALE
  • Eligible Ages:

    16 to 55

Participation Criteria

Inclusion criteria

Women who:

* request elective pregnancy termination in one of the sites participating into the study
* are prescribed mifepristone-misoprostol for this purpose
* provide informed consent to participate in the study.

Exclusion Criteria:

* Participant who is unable to understand or comply with Health Care Professional instructions or medical abortion regimen
* Participant who is unable or unwilling to provide written informed consent.

Study Location

Family Planning Clinic, Moncton City Hospital
Family Planning Clinic, Moncton City Hospital
Moncton, New Brunswick
Canada

Contact Study Team

Women's College Hospital
Women's College Hospital
Toronto, Ontario
Canada

Contact Study Team

Manitoulin Health Centre
Manitoulin Health Centre
Mindemoya, Ontario
Canada

Contact Study Team

Centennial Primary Care
Centennial Primary Care
Kentville, Nova Scotia
Canada

Contact Study Team

Choice in Health Clinic
Choice in Health Clinic
Toronto, Ontario
Canada

Contact Study Team

Mud Creek Medical
Mud Creek Medical
New Minas, Nova Scotia
Canada

Contact Study Team

Study Sponsored By
Linepharma International LTD
Participants Required
More Information
Study ID: NCT04905251